Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Jul;18(1):65–74. doi: 10.1111/j.1365-2125.1984.tb05023.x

The influence of age on renal and extrarenal effects of frusemide.

F Andreasen, U Hansen, S E Husted, C E Mogensen, E B Pedersen
PMCID: PMC1463580  PMID: 6743491

Abstract

The effect of frusemide 80 mg i.v. was compared during 24 h in 10 young and eight elderly healthy male volunteers following a 24 h control period in the ward. During the 30 min following the injection the increments in excretion of urine, sodium, potassium and frusemide were significantly smaller in the elderly. The 24 h increase in sodium excretion was significantly larger in the 0 young and eight elderly healthy male volunteers following a 24 h control period in the ward. During the 30 min following the injection the increments in excretion of urine, sodium, potassium and frusemide were significantly smaller in the elderly. The 24 h increase in sodium excretion was significantly larger in the 0 young and eight elderly healthy male volunteers following a 24 h control period in the ward. During the 30 min following the injection the increments in excretion of urine, sodium, potassium and frusemide were significantly smaller in the elderly. The 24 h increase in sodium excretion was significantly larger in the elderly. The endogenous 24 h creatinine clearance was reduced by 12% (P less than 0.01) in both age groups. The frusemide induced changes in the 8 h serum concentration curves for albumin differed significantly between the two groups (analysis of variance, P less than 0.01). The drug induced increase in albumin concentration became significant in the young 5 min after the injection. In the elderly it took more than 15 min before the increase in serum albumin reached significance. The average maximal increase in albumin concentration was 14.3% in the young and 9.7% in the elderly (P less than 0.05). No difference was seen between the two age groups in the significant frusemide induced increases in the 24 h albumin excretion but in the elderly a significantly larger decrease in the 24 h excretion of beta 2-microglobulin was observed (P less than 0.05). No significant age difference was observed in the initial significant increases in diastolic blood pressure observed in both age groups or between the later changes in systolic blood pressure which was significantly reduced in the young only. The slower haemoconcentration response in the elderly seemed associated with the slower secretion rate of frusemide to the tubular lumen. We found no evidence of an age related difference in tubular cell response to frusemide. It is emphasized that a maximal initial frusemide response in the elderly, in contrast to what was found in the young, probably was not achieved by the 80 mg i.v.

Full text

PDF
66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen F., Christensen C. K., Jacobsen F. K., Jansen J., Mogensen C. E., Pedersen O. L. The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. Eur J Clin Invest. 1982 Jun;12(3):247–255. doi: 10.1111/j.1365-2362.1982.tb01000.x. [DOI] [PubMed] [Google Scholar]
  2. Andreasen F., Christensen C. K., Jakobsen F. K., Mogensen C. E. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol (Copenh) 1981 Sep;49(3):223–229. doi: 10.1111/j.1600-0773.1981.tb00897.x. [DOI] [PubMed] [Google Scholar]
  3. Andreasen F., Hansen U., Husted S. E., Jansen J. A. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol. 1983 Oct;16(4):391–397. doi: 10.1111/j.1365-2125.1983.tb02183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andreasen F., Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15–22. doi: 10.1007/BF00561400. [DOI] [PubMed] [Google Scholar]
  5. Benet L. Z. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm. 1979 Feb;7(1):1–27. doi: 10.1007/BF01059438. [DOI] [PubMed] [Google Scholar]
  6. Bennett W. M., Porter G. A. Endogenous creatinine clearance as a clinical measure of glomerular filtration rate. Br Med J. 1971 Oct 9;4(5779):84–86. doi: 10.1136/bmj.4.5779.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cowley A. W., Jr, Monos E., Guyton A. C. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res. 1974 Apr;34(4):505–514. doi: 10.1161/01.res.34.4.505. [DOI] [PubMed] [Google Scholar]
  8. Cutler R. E., Blair A. D. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet. 1979 Jul-Aug;4(4):279–296. doi: 10.2165/00003088-197904040-00002. [DOI] [PubMed] [Google Scholar]
  9. De Lima J., Caillens H., Beaufils M., Ardaillou R. Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. Clin Nephrol. 1981 May;15(5):246–251. [PubMed] [Google Scholar]
  10. Evrin P. E., Peterson P. A., Wide L., Berggård I. Radioimmunoassay of 2 -microglobulin in human biological fluids. Scand J Clin Lab Invest. 1971 Dec;28(4):439–443. doi: 10.3109/00365517109095721. [DOI] [PubMed] [Google Scholar]
  11. Hesse B., Nielsen I., Lund-Jacobsen H. The early effects of intravenous frusemide on central haemodynamics, venous tone and plasma renin activity. Clin Sci Mol Med. 1975 Dec;49(6):551–555. doi: 10.1042/cs0490551. [DOI] [PubMed] [Google Scholar]
  12. Miles D. W., Mogensen C. E., Gundersen H. J. Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest. 1970 Aug;26(1):5–11. doi: 10.3109/00365517009049206. [DOI] [PubMed] [Google Scholar]
  13. Pedersen E. B. Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension. Acta Med Scand Suppl. 1980;636:1–66. [PubMed] [Google Scholar]
  14. Perez J., Sitar D. S., Ogilvie R. I. Kinetic disposition and diuretic effect of frusemide in acute pulmonary oedema. Br J Clin Pharmacol. 1980 May;9(5):471–478. doi: 10.1111/j.1365-2125.1980.tb05842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Robertson G. L., Mahr E. A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973 Sep;52(9):2340–2352. doi: 10.1172/JCI107423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Szczepańska-Sadowska E. Hemodynamic effects of a moderate increase of the plasma vasopressin level in conscious dogs. Pflugers Arch. 1973;338(4):313–322. doi: 10.1007/BF00586073. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES